



Hemogenyx Pharmaceuticals plc
29 May 2020

Hemogenyx Pharmaceuticals plc

("Hemogenyx" or the "Company")

Total Voting Rights

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company consists of 397,921,969 ordinary shares of 1 penny each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 397,921,969.

The figure of 397,921,969 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Enquiries:

Hemogenyx Pharmaceuticals plc

<https://hemogenyx.com>

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

headquarters@hemogenyx.com

Sir Marc Feldmann, Chairman

SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Soltan Tagiev

Peterhouse Capital Limited

Tel: +44 (0)20 7469 0930



Lucy Williams, Duncan Vasey, Charles Goodfellow

US Media enquiries

Lowell Goodman

Tel: +1 (323) 646-3249

lowell@corbomitecomms.com